CL2021001614A1 - Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas - Google Patents

Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas

Info

Publication number
CL2021001614A1
CL2021001614A1 CL2021001614A CL2021001614A CL2021001614A1 CL 2021001614 A1 CL2021001614 A1 CL 2021001614A1 CL 2021001614 A CL2021001614 A CL 2021001614A CL 2021001614 A CL2021001614 A CL 2021001614A CL 2021001614 A1 CL2021001614 A1 CL 2021001614A1
Authority
CL
Chile
Prior art keywords
mitochondrial
cscs
therapeutic agent
stem cells
cancer stem
Prior art date
Application number
CL2021001614A
Other languages
English (en)
Inventor
Michael P Lisanti
Federica Sotgia
Marco Fiorillo
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of CL2021001614A1 publication Critical patent/CL2021001614A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las células madre cancerosas (CSCs) pueden ser erradicadas a través de una estrategia terapéutica novedosa que implica, en algunas modalidades, antibióticos aprobados por la FDA y suplementos dietéticos. El presente planteamiento da por resultado de manera efectiva la erradicación sinérgica de CSCs a través de la inhibición de la biogénesis mitocondrial en CSCs durante el estrés oxidante mitocondrial inducido, sin inhibir las células normales. Las modalidades pueden incluir un agente terapéutico que inhibe la biogénesis mitocondrial y fija como objetivo el ribosoma mitocondrial grande, un agente terapéutico que inhibe la biogénesis mitocondrial y fija como objetivo el ribosoma mitocondrial pequeño y un agente terapéutico que se comporta como un pro-oxidante o induce el estrés oxidante mitocondrial. Las composiciones de acuerdo con el presente planteamiento inhibieron la propagación de CSC por 90% en líneas de células MCF7 ER(+) durante estudios preliminares, con una reducción confirmada en el consumo de oxígeno mitocondrial y la producción de ATP. Algunas modalidades incluyen concentraciones sub-antimicrobianas de antibiótico, lo que minimiza en consecuencia los problemas de resistencia a antibióticos. En algunas modalidades, uno o más agentes terapéuticos se conjugan con una señal de fijación de objetivos.
CL2021001614A 2018-12-17 2021-06-17 Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas CL2021001614A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862780488P 2018-12-17 2018-12-17
US201962804411P 2019-02-12 2019-02-12

Publications (1)

Publication Number Publication Date
CL2021001614A1 true CL2021001614A1 (es) 2022-01-14

Family

ID=71102312

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001614A CL2021001614A1 (es) 2018-12-17 2021-06-17 Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas

Country Status (20)

Country Link
US (1) US20220040316A1 (es)
EP (1) EP3897658A4 (es)
JP (1) JP7487205B2 (es)
KR (1) KR20210104829A (es)
CN (1) CN113573715A (es)
AU (1) AU2019403048A1 (es)
BR (1) BR112021011963A2 (es)
CA (1) CA3123838A1 (es)
CL (1) CL2021001614A1 (es)
CO (1) CO2021008999A2 (es)
CR (1) CR20210350A (es)
DO (1) DOP2021000124A (es)
EC (1) ECSP21052747A (es)
IL (1) IL284056A (es)
MX (1) MX2021007345A (es)
PE (1) PE20211551A1 (es)
PH (1) PH12021551434A1 (es)
SG (1) SG11202106516VA (es)
WO (1) WO2020131696A1 (es)
ZA (1) ZA202104255B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229499A1 (en) * 2020-05-13 2021-11-18 Lunella Biotech, Inc. Myristoyl derivatives of 9-amino-doxycycline for targeting cancer stem cells and preventing metastasis
WO2023200824A1 (en) * 2022-04-13 2023-10-19 The Wistar Institute Of Anatomy And Biology Delivery system to target gram-negative bacteria

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149776C (da) * 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
JP4573925B2 (ja) * 1998-07-09 2010-11-04 アベンティス・ファーマ・ソシエテ・アノニム 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
RU2223103C1 (ru) * 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
CN1837229A (zh) * 2005-08-05 2006-09-27 济南思创生物技术有限公司 克拉霉素衍生物及其制备方法和药物应用
CA2745376A1 (en) * 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
US9180134B2 (en) * 2011-08-18 2015-11-10 Ecole Polytechnique Federale De Lausanne (Epel) Mitochondrial ribosomal proteins as aging regulators
GB201217310D0 (en) * 2012-09-27 2012-11-14 C10 Pharma As Compounds
CN103536530A (zh) * 2013-10-30 2014-01-29 王玉万 盐酸多西环素长效注射剂及制备方法
NZ756854A (en) * 2017-03-15 2022-02-25 Lunella Biotech Inc Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
WO2018195434A1 (en) * 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
RU2019142102A (ru) * 2017-05-19 2021-06-21 Лунелла Байотек, Инк. Антимитосцины: направленные ингибиторы митохондриального биогенеза для эрадикации злокачественных стволовых клеток

Also Published As

Publication number Publication date
PH12021551434A1 (en) 2021-12-06
AU2019403048A1 (en) 2021-07-08
JP2022516414A (ja) 2022-02-28
ECSP21052747A (es) 2021-08-31
EP3897658A4 (en) 2022-10-19
SG11202106516VA (en) 2021-07-29
DOP2021000124A (es) 2021-08-15
EP3897658A1 (en) 2021-10-27
JP7487205B2 (ja) 2024-05-20
WO2020131696A1 (en) 2020-06-25
CA3123838A1 (en) 2020-06-25
MX2021007345A (es) 2021-07-15
ZA202104255B (en) 2023-01-25
CR20210350A (es) 2021-09-27
CN113573715A (zh) 2021-10-29
PE20211551A1 (es) 2021-08-16
KR20210104829A (ko) 2021-08-25
BR112021011963A2 (pt) 2021-09-08
IL284056A (en) 2021-08-31
CO2021008999A2 (es) 2021-07-30
US20220040316A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CL2021001614A1 (es) Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas
ZA202202712B (en) Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
CO2020006472A2 (es) Compuestos de derivados de trifenilfosfonio para erradicar células madre cancerosas
UY39417A (es) Agentes de arni para inhibir la expresión de dux4, composiciones de dichos agentes, y métodos de uso
AR110419A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
PH12019502062A1 (en) Skin barrier composition
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
WO2018085816A1 (en) Prooxidant cancer chemo-suppressors and chemo-protectors and methods of use related thereto
CL2021000529A1 (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
BR112017026140A2 (pt) método para inibir o crescimento ou a proliferação de células cancerígenas, método para induzir apoptose em célula cancerígena, método para tratar câncer, composição e seu uso
CO2021009008A2 (es) Terapias de combinación triple para anti-envejecimiento
BR112015020178A2 (pt) composição com propriedades de inflamação reduzidas para pele biológica e método de redução da inflamação do tecido biológico
PE20220250A1 (es) Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
CO2020006648A2 (es) Derivados de imidazopiridina y su uso como medicamento
CO2021004612A2 (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento
BR112022014650A2 (pt) Derivado de adamantila dissubstituído ou sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para suprimir o crescimento de câncer compreendendo o mesmo como ingrediente ativo
BR112017002911A2 (pt) composição para prevenção ou tratamento de obesidade contendo ácido alfa-lipóico e n-acetilcisteína como ingredientes ativos
BR112022009142A2 (pt) Derivados de indol macrocíclicos como inibidores de mcl-1
BR112019006633A2 (pt) combinações farmacêuticas de inibidor de histona desacetilase e inibidor de proteassoma ou fármaco imunomodulador para o tratamento de câncer hematológico
Magalhães et al. Melissa Officinalis L. ethanolic extract interferes with cell cycle and induces apoptosis of non-small cell lung cancer cells
Shim Synthesis and NRF2 activating ability of thiourea and vinyl sulfoxide derivatives
BRPI0515465A (pt) métodos de inibição do crescimento de célula de tumor e de tratamento de cáncer, incluindo cáncer dependente de hormÈnio e cáncer de próstata e usos de selenato ou sal farmaceuticamente aceitável do mesmo
UY37099A (es) Tratamiento de ulceras gastricas en animales no humanos utilizando formulaciones no recubiertas ni protegidas entéricamente que comprenden polímeros de proantocianidina o extractos botanicos derivados de croton o calophyllum
AR110598A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
BR112015029280A2 (pt) dencichine para a utilização no tratamento da trombocitopenia e para a utilização na fabricação de um medicamento